z-logo
open-access-imgOpen Access
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer
Author(s) -
Sara Gagno,
Michele Bartoletti,
Chiara Romualdi,
Elena Poletto,
Simona Scalone,
Roberto Sorio,
Martina Zanchetta,
Elena De Mattia,
Rossana Roncato,
Erika Cecchin,
Giorgio Giorda,
Giuseppe Toffoli
Publication year - 2020
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs-2020-0049
Subject(s) - medicine , hazard ratio , oncology , progression free survival , ovarian cancer , confidence interval , taxane , overall survival , cancer , breast cancer
Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI). Results: ABCG2 rs3219191D>I, UGT1A rs10929302G>A and UGT1A rs2741045T>C polymorphisms were significantly associated with all three parameters (OS, PFS and PFI) and were used to generate a score. Patients in high-risk group had a poorer OS (hazard ratio [HR]: 1.8; 95% CI: 1.3–2.7; p = 0.0019), PFS (HR: 2.0; 95% CI: 1.4–2.9; p < 0.0001) and PFI (HR: 1.9; 95% CI: 1.4–2.8; p = 0.0002) compared with those in low-risk group. Conclusion: The prognostic-score including polymorphisms involved in drug and estrogen pathways stratifies OCP according to OS, PFS and PFI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here